INDICATION AND IMPORTANT SAFETY INFORMATION
TOBI® Podhaler® (Tobramycin Inhalation Powder) 28 mg per capsule is indicated for the management of cystic fibrosis patients with Pseudomonas aeruginosa.  ...More

LEARN HOW TOBI® PODHALER® MAY FIT INTO
YOUR PATIENT’S DAY

ADMINISTERED IN 2 TO 7 MINUTES1,*

  • Take 4 capsules for inhalation twice daily: 4 in the morning and 4 in the evening
    • The powder from all 4 capsules must be inhaled to receive the full dose of 112 mg
    • Inhale 2 times from each capsule in order to empty it
  • 28 days on and 28 days off

PORTABLE1,2

  • Compact and lightweight
  • No refrigeration or power source required

QUICK CLEANUP1

  • No disinfection required
  • Wipe clean with a dry cloth

* As observed in a clinical trial.1

Important Dosing Considerations1

  • Patients and caregivers should be initially trained by their health care provider on the proper use of TOBI Podhaler
  • TOBI Podhaler capsules must not be swallowed
  • Capsules are for use with the Podhaler device only
  • Capsules are for oral inhalation only
  • Each dose of 4 capsules should be taken as close to 12 hours apart as possible; each dose should not be taken less than 6 hours apart
  • Capsules should always be stored in the blister card; each capsule should only be removed IMMEDIATELY BEFORE USE

Becky

14 YEARS OLD | MOVIE BUFF

TOBI Podhaler is portable, so Becky can fit it in her purse when she goes out to the movies with her friends.

Not an actual patient.

A centralized support and access program for TOBI® Podhaler® patients

Learn more

SET TREATMENT EXPECTATIONS

Inform your patients about what to expect while taking TOBI® Podhaler®

Learn more

ADMINISTRATION INFORMATION

Administration information and helpful tips for patients taking TOBI® Podhaler®

Learn more

Share

To share this website with other health care professionals, please choose your email service provider:

INDICATION AND IMPORTANT SAFETY INFORMATION

INDICATION

TOBI® Podhaler® (Tobramycin Inhalation Powder) 28 mg per capsule is indicated for the management of cystic fibrosis patients with Pseudomonas aeruginosa.

Safety and efficacy have not been demonstrated in patients under the age of 6 years, patients with forced expiratory volume in
1 second
(FEV1) <25% or >80% predicted, or patients colonized with Burkholderia cepacia.